Why the study?
Many existing randomised controlled trials lack sufficient power to assess primary kidney outcomes, leaving unclear whether statin therapy offers a clinically meaningful reno-protective effect in patients with CKD.
Does the initiation of statin therapy reduce the risk of all-cause mortality and eGFR deterioration in adults with chronic kidney disease?
Does the initiation of statin therapy reduce the risk of all-cause mortality and eGFR deterioration in adults with chronic kidney disease?
Initiating statin therapy in patients with chronic kidney disease is associated with modest but significant reductions in all-cause mortality and adverse kidney outcomes over a 10-year period.
Answers are grounded in this paper and cite their sources.
Supports statin initiation in CKD for lower mortality and eGFR decline; leaves open confirmation in randomized trials.
Background: Many existing randomised controlled trials lack sufficient power to assess primary kidney outcomes. This study aimed to evaluate whether statin therapy offers a clinically meaningful reno-protective effect in patients with chronic kidney disease (CKD). Findings: (ITT: 0.91 [0.89-0.93]; PP: 0.77 [0.74-0.80]), ≥50% eGFR decline (ITT: 0.95 [0.93-0.98]; PP: 0.89 [0.84-0.93]), and composite outcomes (ITT: 0.96 [0.94-0.97]; PP: 0.90 [0.88-0.92]). Statin therapy initiation was also associated significantly with reduced risk of ≥30% eGFR decline using PP approach (0.94 [0.92-0.96]). Interpretation: Over a 10-year follow-up period, initiating statin therapy in patients with CKD was associated with a small yet significant decrease in all-cause mortality and a modest reno-protective effect. Future research should aim to clarify the effects of statin intensity, duration, and adherence.
No takes yet. Share an insight, caveat, or question.
Wong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: